Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CFO Sells 2,362 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the sale, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Erick Lucera also recently made the following trade(s):

• On Wednesday, May 13th, Erick Lucera sold 1,448 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.36, for a total transaction of $26,585.28.

Dyne Therapeutics Price Performance

NASDAQ DYN traded up $0.33 during trading hours on Friday, reaching $20.94. The company’s stock had a trading volume of 5,436,037 shares, compared to its average volume of 2,013,259. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -6.50 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company’s 50-day moving average is $18.43 and its two-hundred day moving average is $18.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) earnings per share. On average, equities analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics during the 1st quarter worth $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics during the fourth quarter worth about $84,000. Steward Partners Investment Advisory LLC boosted its position in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Dyne Therapeutics by 275.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

DYN has been the subject of a number of research analyst reports. HC Wainwright reduced their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 15th. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research report on Friday. They set a “buy” rating for the company. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.